Showing results (81-90 of 584) with videos related to
Sort By:
Pageof 59
Current Opinion in Oncology|January 13, 2016
Predictive biomarkers for programmed death-1/programmed death ligand immune checkpoint inhibitors in nonsmall cell lung cancerJordi Remon, Nathalie Chaput, David PlanchardNPJ Precision Oncology|July 17, 2021
Circulating tumor cell copy-number heterogeneity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsMarianne Oulhen, Patrycja Pawlikowska, Tala Tayoun, et al.Cardiovascular and Interventional Radiology|November 7, 2019
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung CancerPernelle Lavaud, Benjamin Besse, Thierry de Baere, et al.European Journal of Nuclear Medicine and Molecular Imaging|November 23, 2019
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitorsRomain-David Seban, Laura Mezquita, Arnaud Berenbaum, et al.European Journal of Cancer (Oxford, England : 1990)|February 9, 2023
Clinical outcomes by infusion timing of immune checkpoint inhibitors in patients with advanced non-small cell lung cancerAdrien Rousseau, Marco Tagliamento, Edouard Auclin, et al.Cancer Research|May 3, 2017
Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i>-Rearranged Non-Small Cell Lung Cancer PatientsEmma Pailler, Marianne Oulhen, Isabelle Borget, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung CancersFrancesco Facchinetti, Yohann Loriot, Mei-Shiue Kuo, et al.European Journal of Cancer (Oxford, England : 1990)|June 10, 2026
Efficacy of alectinib for ALK-positive NSCLC according to tumor burden and body mass index: A pooled analysis of the randomized phase III trials ALEX and J-ALEXMarco Tagliamento, Marco Bruzzone, Eva Blondeaux, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2020
Current Panorama and Challenges for Neoadjuvant Cancer ImmunotherapyJose Carlos Benitez, Jordi Remon, Benjamin BesseBulletin Du Cancer|December 6, 2006
[Neoadjuvant chemotherapy in non small cell lung cancer]Benjamin Besse, Stéphane Vignot, Thierry Le ChevalierPageof 59